FDA Grants Full Approval to Eli Lilly's Inluriyo plus Verzenio for ESR1 Mutated Advanced Breast Cancer

Metastatic breast cancer that is estrogen receptor positive and HER2 negative remains the most common form of advanced breast cancer, and for years the standard first step has been an aromatase inhibitor, often paired with a CDK4/6 inhibitor. Most patients eventually progress, and a frequent driver of that resistance is a mutation in ESR1, the gene encoding the estrogen receptor. Roughly half of patients with ER-positive, HER2-negative metastatic disease develop an ESR1 mutation during or after treatment with that class of hormone-blocking medicines, according to Eli Lilly and Company.

On September 18, 2026, the U.S. Food and Drug Administration granted full approval to imlunestrant, sold as Inluriyo, in combination with abemaciclib, sold as Verzenio, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. Both drugs are manufactured by Eli Lilly and Company. The decision converts an earlier accelerated pathway into a full endorsement and covers a population defined by a specific genomic biomarker rather than by clinical features alone.

The approval rests on the Phase 3 EMBER-3 trial, and it arrives less than a year after imlunestrant received its first clearance as a monotherapy in the same ESR1-mutated setting in September 2025. The combination is entirely oral, taken at home, and Lilly says it does not require new monitoring beyond what abemaciclib already demands. For patients who have already exhausted an aromatase inhibitor, the regimen offers a targeted switch rather than a generic change of endocrine agent.

Key Facts

The FDA approved the combination alongside a companion diagnostic. On September 18, 2026, the agency also authorized the Guardant360 CDx assay, developed by Guardant Health, to identify patients whose tumors carry ESR1 mutations and who are therefore eligible for imlunestrant plus abemaciclib. The label specifies adults with ER-positive, HER2-negative advanced or metastatic disease, as detected by an FDA-authorized test, whose cancer has progressed following at least one line of endocrine therapy.

CancerNetwork reported on September 18, 2026 that the supporting evidence came from EMBER-3 (NCT04975308), a randomized, open-label, active-controlled, multicenter trial that enrolled 874 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with an aromatase inhibitor, either alone or in combination with a CDK4/6 inhibitor. Patients eligible for a PARP inhibitor were excluded. Participants were randomly assigned 1:1:1 to imlunestrant monotherapy (n=331), imlunestrant plus abemaciclib (n=213), or an investigator's choice of fulvestrant or exemestane (n=330).

In the exploratory subgroup of 159 patients with ESR1-mutated tumors, median progression-free survival was 11.1 months (95% CI: 7.4, 13.7) in the imlunestrant plus abemaciclib arm and 5.5 months (95% CI: 3.8, 7.2) in the imlunestrant-alone arm. The hazard ratio for progression or death was 0.53 (95% CI: 0.35, 0.80). Objective response rate was 35% (95% CI: 22, 48) with the combination and 15% (95% CI: 7, 23) with imlunestrant alone. Lilly described the result as doubling median progression-free survival among patients with ESR1-mutated metastatic breast cancer.

Edgen Tech reported on September 18, 2026 that most adverse events were grade 1 or 2 and that neither drug carries a boxed warning. Diarrhea occurred in 86% of patients on the combination, with grade 3 or 4 diarrhea in 9%; neutrophil counts fell in 86%, with grade 3 or 4 decreases in 21%. Permanent discontinuation of imlunestrant because of adverse reactions occurred in 1% of combination-arm patients, and of abemaciclib in 3.4%. The label lists warnings for diarrhea, neutropenia, interstitial lung disease or pneumonitis, hepatotoxicity, venous thromboembolism, and embryo-fetal toxicity.

The FDA stated on September 18, 2026 that the recommended dosage is imlunestrant 400 mg orally once daily on an empty stomach and abemaciclib 150 mg orally twice daily, continued until disease progression or unacceptable toxicity. Eli Lilly and Company said on September 18, 2026 that Jacob Van Naarden, executive vice president and president of Lilly Oncology, called Inluriyo the leading treatment option for people with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, reaching over half of all patients starting an oral SERD, and that the full approval extends the combination's confirmed benefit without burdensome monitoring requirements.

Analysis

The most striking feature of the EMBER-3 result is not the size of the trial but the size of the effect within a molecularly defined subgroup. A hazard ratio of 0.53 means patients on the combination had roughly half the relative risk of their cancer worsening or of death during the study period compared with those on imlunestrant alone, a 47% reduction. What this really means is that the biology of ESR1 mutations can be exploited twice: once by switching the endocrine backbone to an oral SERD, and again by retaining a CDK4/6 inhibitor that the tumor may still depend on.

That said, the evidence comes with caveats. The ESR1-mutated analysis was an exploratory subgroup of 159 patients, and at the interim analysis overall survival data were immature, with 35% of deaths in patients with ESR1-mutated tumors. The trial was not powered to compare the combination against investigator's choice of fulvestrant or exemestane in that subgroup. Regulators evidently judged the progression-free survival benefit, the objective response rate, and the manageable safety profile sufficient for full approval, but the survival question remains open.

Commercially, the decision strengthens Lilly's position in a field where oral SERDs are competing to displace injectable fulvestrant. Edgen Tech reported on September 18, 2026 that imlunestrant competes with fulvestrant and that the drug now reaches more than half of all patients starting an oral SERD. The all-oral combination also avoids the clinic visits associated with intramuscular fulvestrant, though it inherits abemaciclib's gastrointestinal and hematologic side effects.

The bigger picture here is that biomarker testing is becoming the gatekeeper for treatment selection in metastatic breast cancer. The FDA's simultaneous approval of the Guardant360 CDx assay turns ESR1 status into an actionable result rather than an incidental finding, and it shifts the practical question for oncologists from whether to test to when to test, since the label specifies disease progression after at least one line of endocrine therapy.

Why It Matters

For patients, the approval adds a new option at a point where options historically narrow. Roughly half of ER-positive, HER2-negative metastatic patients develop ESR1 mutations during or after aromatase inhibitor treatment, according to Lilly, and that group now has a regimen that more than doubles median progression-free survival compared with imlunestrant alone in the EMBER-3 subgroup. Principal investigator Komal Jhaveri, MD, FACP, FASCO, of Memorial Sloan Kettering Cancer Center, said in a statement reported by CancerNetwork on September 18, 2026 that switching both the endocrine therapy and the CDK4/6 inhibitor at progression achieved a median PFS of 11.1 months with a safety profile consistent with each medicine individually.

For the health system, the approval reinforces a shift toward oral regimens that can be taken at home. The label requires no new monitoring, and most toxicities were grade 1 or 2. The regimen does carry real risks, including grade 3 or 4 neutropenia in 21% of patients on the combination and grade 3 or 4 diarrhea in 9%, so community oncology practices will need to manage those events without the safety net of an infusion suite.

For drug developers, the decision is a reminder that a biomarker-defined subgroup can support a full approval when the effect size is large and the mechanism is clear. It also raises the bar for competitors: any new agent in this setting will be measured against a median progression-free survival of 11.1 months and a hazard ratio of 0.53.

Next Up

Lilly is not stopping at metastatic disease. Imlunestrant is being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for ER-positive, HER2-negative early-stage breast cancer at increased risk of recurrence. Lilly says EMBER-4 is the largest adjuvant oral SERD trial, with more than 8,000 patients enrolled worldwide across more than 650 sites in more than 30 countries. Results there could move the drug earlier in the treatment sequence.

The company is also advancing LY4064809, an investigational PI3K-alpha inhibitor, into the Phase 3 PIKALO-2 study. For now, the September 18, 2026 approval stands as the second FDA clearance for imlunestrant in under a year and the first full approval for the combination, giving clinicians a defined, biomarker-driven regimen for a population that had been waiting for one.